Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives
Ashagrachew Tewabe Yayehrad,Ebrahim Abdela Siraj,Gebremariam Birhanu Wondie,Atlaw Abate Alemie,Manaye Tamrie Derseh,Abyou Seyfu Ambaye
DOI: https://doi.org/10.2147/IJN.S327334
IF: 7.033
2021-08-24
International Journal of Nanomedicine
Abstract:Ashagrachew Tewabe Yayehrad, 1, 2 Ebrahim Abdela Siraj, 1, 2 Gebremariam Birhanu Wondie, 1 Atlaw Abate Alemie, 1, 3 Manaye Tamrie Derseh, 1, 4 Abyou Seyfu Ambaye 4 1 Department of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; 2 Department of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia; 3 Ethiopian Food and Drug Authority (EFDA), Federal Ministry of Health (FMoH), Addis Ababa, Ethiopia; 4 Departement of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, Ethiopia Correspondence: Ashagrachew Tewabe Yayehrad Department of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, PO Box: 9086, Addis Ababa, Ethiopia Tel + 251912960525 Email A serious viral infectious disease was introduced to the globe by the end of 2019 that was seen primarily from China, but spread worldwide in a few months to be a pandemic. Since then, accurate prevention, early detection, and effective treatment strategies are not yet outlined. There is no approved drug to counter its worldwide transmission. However, integration of nanostructured delivery systems with the current management strategies has promised a pronounced opportunity to tackle the pandemic. This review addressed the various promising nanotechnology-based approaches for the diagnosis, prevention, and treatment of the pandemic. The pharmaceutical, pharmacoeconomic, and regulatory aspects of these systems with currently achieved or predicted beneficial outcomes, challenges, and future perspectives are also highlighted. Keywords: nano-vaccine, nano-theranostics, nanoparticles, nanotechnology, SARS-CoV-2 The end of 2019 came with a serious viral infectious disease which was seen primarily from China, but spread worldwide and was declared as a pandemic in a few months. The outbreak officially became a pandemic in March 2020. 1,2 The World Health Organization (WHO) termed this novel and vastly spreading disease as "coronavirus disease-2019" (COVID-19), and the viral agent as "severe acute respiratory syndrome – coronavirus-2" (SARS-CoV-2). Since then, it has been a massively challenging global epidemic with combined health-related and economic destitution worldwide. 3,4 SARS-CoV-2 seriously affects the respiratory system by triggering an acute immunological response which is the main cause of death with a fatality rate per country of 0.05–19.4%. The SARS-CoV-2 results in an increased mucous secretion, which then clogs the alveoli and prevents blood oxygenation. Its endocytosis and replication in the lungs generates an acute immune response and tissue inflammation by triggering the signal cascade through cytokine storms. The virus can also spread to the digestive system and other major organs like the kidney and liver. It has the potential to access every tissue that expresses angiotensin-converting enzyme-2 (ACE2) receptor. 5–7 Structural analyses of SARS-CoV-2 showed that it has spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins which are responsible for its cell attachment and entry mechanisms. Management strategies are based on these structural features. More than 80% of SARS-CoV-2 and host cell membrane interactions occur due to the presence of the S protein that is a special characteristic of the pathogenic cell for treatment strategies. 8,9 Human coronaviruses (HCoVs) are among the top 10 fatal viruses. SARS-CoV, one of the HCoVs, has a mortality rate of up to 10%. Currently, there are approximately 176 million confirmed cases and about 3,811,561 SARS-CoV-2 related deaths worldwide. 10 Fever (85.6%), cough (68.7%), and fatigue (39.4%) are among the major reported symptoms. Dyspnea, headache, loss of appetite, loss of taste and smell, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain are the less common symptoms of the disease. The presence of comorbidities such as hypertension, diabetes, and coronary heart disease may further complicate the problem. 11 There may be a two-week incubation period with mild to moderate symptoms followed by a high infection rate. Reports showed that there are also asymptomatic transmissions. Currently, the viral outbreak has created a global crisis related to disastrous live losses and financial collapses. 1,12 The two main ways of COVID-19 transmission are direct air-to-air transmission during sneezing, talking, and coughing; and direct contact with contaminated surface/object. 13,14 Personal hygiene, persona -Abstract Truncated-